Technology | June 28, 2006

Minimally Invasive Laser Solution for Atrial Fibrillation

A 1064 nm wavelength laser technology, the Atrilaze Surgical Ablation system complements its existing 810 nm technology.
The system is indicated for delivery of laser light to soft tissue, including cardiac tissue, during surgical procedures. Indications include the incision, excision, dissection, vaporization, ablation or coagulation of soft tissue.
Because it can be delivered through a 600 micron optical fiber, the Atrilaze system is designed for very small incisions, potentially enabling a stand-alone (closed-chest, beating heart) procedure.


Related Content

News

Sept. 8, 2026 — Abbot has announced that it has received U.S. Food and Drug Administration (FDA) approval for the ...

Home September 08, 2026
Home
News

Aug. 31, 2026 — At the European Society of Cardiology Congress in Munich, Abbott announced new late-breaking 12-month ...

Home September 02, 2026
Home
News

July 8, 2026 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy ...

Home July 08, 2026
Home
News

May 21, 2026 — Adagio Medical Holdings, a provider of catheter ablation technologies for treating cardiac arrhythmias ...

Home May 22, 2026
Home
News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
Subscribe Now